Skip to main content
Erschienen in: Inflammation 2/2022

17.11.2021 | Review

AGE/Non-AGE Glycation: An Important Event in Rheumatoid Arthritis Pathophysiology

verfasst von: Monu, Prachi Agnihotri, Sagarika Biswas

Erschienen in: Inflammation | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory, autoimmune disease that gradually affects the synovial membrane and joints. Many intrinsic and/or extrinsic factors are crucial in making RA pathology challenging throughout the disease. Substantial enzymatic or non-enzymatic modification of proteins driving inflammation has gained a lot of interest in recent years. Endogenously modified glycated protein influences disease development linked with AGEs/non-AGEs and is reported as a disease marker. In this review, we summarized current knowledge of the differential abundance of glycated proteins by compiling and analyzing a variety of AGE and non-AGE ligands that bind with RAGE to activate multi-faceted inflammatory and oxidative stress pathways that are pathobiologically associated with RA-fibroblast-like synoviocytes (RA-FLS). It is critical to comprehend the connection between oxidative stress and inflammation generation, mediated by glycated protein, which may bind to the receptor RAGE, activate downstream pathways, and impart immunogenicity in RA. It is worth noting that AGEs and non-AGEs ligands play a variety of functions, and their functionality is likely to be more reliant on pathogenic states and severity that may serve as biomarkers for RA. Screening and monitoring of these differentially glycated proteins, as well as their stability in circulation, in combination with established pre-clinical characteristics, may aid or predict the onset of RA.

Graphical abstract

Literatur
1.
Zurück zum Zitat Guo, Q., Y. Wang, D. Xu, J. Nossent, N.J. Pavlos, and J. Xu. 2018. Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies. Bone Research 6 (15): 1–14. Guo, Q., Y. Wang, D. Xu, J. Nossent, N.J. Pavlos, and J. Xu. 2018. Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies. Bone Research 6 (15): 1–14.
3.
Zurück zum Zitat Aletaha, D., T. Neogi, A.J. Silman, J. Funovits, D.T. Felson, C.O. Bingham, N.S. Birnbaum, G.R. Burmester, V.P. Bykerk, M.D. Cohen, B. Combe, K.H. Costenbader, M. Dougados, P. Emery, G. Ferraccioli, J.M. Hazes, K. Hobbs, T.W. Huizinga, A. Kavanaugh, J. Kay, T.K. Kvien, T. Laing, P. Mease, H.A. Ménard, L.W. Moreland, R.L. Naden, T. Pincus, J.S. Smolen, E. Stanislawska-Biernat, D. Symmons, P.P. Tak, K.S. Upchurch, J. Vencovský, F. Wolfe, and G. Hawker. 2010. Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatology 62 (9): 2569–2581. Aletaha, D., T. Neogi, A.J. Silman, J. Funovits, D.T. Felson, C.O. Bingham, N.S. Birnbaum, G.R. Burmester, V.P. Bykerk, M.D. Cohen, B. Combe, K.H. Costenbader, M. Dougados, P. Emery, G. Ferraccioli, J.M. Hazes, K. Hobbs, T.W. Huizinga, A. Kavanaugh, J. Kay, T.K. Kvien, T. Laing, P. Mease, H.A. Ménard, L.W. Moreland, R.L. Naden, T. Pincus, J.S. Smolen, E. Stanislawska-Biernat, D. Symmons, P.P. Tak, K.S. Upchurch, J. Vencovský, F. Wolfe, and G. Hawker. 2010. Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatology 62 (9): 2569–2581.
4.
Zurück zum Zitat Smolen, J.S., D. Aletaha, A. Barton, G.R. Burmester, P. Emery, G.S. Firestein, A. Kavanaugh, I.B. McInnes, D.H. Solomon, V. Strand, and K. Yamamoto. 2018. Rheumatoid arthritis. Nature Reviews Disease Primers 4 (18001): 1–23. Smolen, J.S., D. Aletaha, A. Barton, G.R. Burmester, P. Emery, G.S. Firestein, A. Kavanaugh, I.B. McInnes, D.H. Solomon, V. Strand, and K. Yamamoto. 2018. Rheumatoid arthritis. Nature Reviews Disease Primers 4 (18001): 1–23.
5.
Zurück zum Zitat Fang, Q., and O, Jiaxin, and K.S. Nandakumar. 2019. Autoantibodies as diagnostic markers and mediator of joint inflammation in arthritis. Mediators of Inflammation 2019 (6363086): 22. Fang, Q., and O, Jiaxin, and K.S. Nandakumar. 2019. Autoantibodies as diagnostic markers and mediator of joint inflammation in arthritis. Mediators of Inflammation 2019 (6363086): 22.
6.
Zurück zum Zitat Carubbi, F., A. Alunno, R. Gerli, and R. Giacomelli. 2019. Post-translational modifications of proteins: Novel insights in the autoimmune response in rheumatoid arthritis. Cells 8 (657): 1–13. Carubbi, F., A. Alunno, R. Gerli, and R. Giacomelli. 2019. Post-translational modifications of proteins: Novel insights in the autoimmune response in rheumatoid arthritis. Cells 8 (657): 1–13.
7.
Zurück zum Zitat Santos, A.L., and A.B. Lindner. 2017. Protein post translational modifications: Roles in aging and age-related disease. Oxidative Medicine and Cellular Longevity 2017: 5716409.PubMedPubMedCentral Santos, A.L., and A.B. Lindner. 2017. Protein post translational modifications: Roles in aging and age-related disease. Oxidative Medicine and Cellular Longevity 2017: 5716409.PubMedPubMedCentral
8.
Zurück zum Zitat Harmel, R., and D. Fiedler. 2018. Features and regulation of non-enzymatic post-translational modifications. Nature Chemical Biology 14: 244–252.PubMed Harmel, R., and D. Fiedler. 2018. Features and regulation of non-enzymatic post-translational modifications. Nature Chemical Biology 14: 244–252.PubMed
9.
Zurück zum Zitat DeGroot, L., H. Hinkema, J. Westra, A.J. Smit, C.G. Kallenberg, M. Bijl, and M.D. Posthumus. 2011. Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease. Arthritis Research & Therapy 13 (6): R205. DeGroot, L., H. Hinkema, J. Westra, A.J. Smit, C.G. Kallenberg, M. Bijl, and M.D. Posthumus. 2011. Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease. Arthritis Research & Therapy 13 (6): R205.
10.
Zurück zum Zitat Ansari, N.A., and D. Dash. 2013. Amadori glycated proteins: Role in production of autoantibodies in diabetes mellitus and effect of inhibitors on non-enzymatic glycation. Aging and Disease 4 (1): 50–56.PubMed Ansari, N.A., and D. Dash. 2013. Amadori glycated proteins: Role in production of autoantibodies in diabetes mellitus and effect of inhibitors on non-enzymatic glycation. Aging and Disease 4 (1): 50–56.PubMed
11.
Zurück zum Zitat Welsh, K.J., M.S. Kirkman, and D.B. Sacks. 2016. Role of glycated proteins in the diagnosis and management of diabetes: Research gaps and future directions. Diabetes Care 39 (8): 1299–1306.PubMedPubMedCentral Welsh, K.J., M.S. Kirkman, and D.B. Sacks. 2016. Role of glycated proteins in the diagnosis and management of diabetes: Research gaps and future directions. Diabetes Care 39 (8): 1299–1306.PubMedPubMedCentral
12.
Zurück zum Zitat Younessi, P., and A. Yoonessi. 2011. Advanced glycation end-products and their receptor-mediated roles: Inflammation and oxidative stress. The Iranian Journal of Medical Sciences 36 (3): 154–166.PubMed Younessi, P., and A. Yoonessi. 2011. Advanced glycation end-products and their receptor-mediated roles: Inflammation and oxidative stress. The Iranian Journal of Medical Sciences 36 (3): 154–166.PubMed
13.
Zurück zum Zitat Sharma, C., A. Kaur, S.S. Thind, B. Singh, and S. Raina. 2015. Advanced glycation end-products (AGEs): An emerging concern for processed food industries. The Journal of Food Science and Technology 52 (12): 7561–7576.PubMed Sharma, C., A. Kaur, S.S. Thind, B. Singh, and S. Raina. 2015. Advanced glycation end-products (AGEs): An emerging concern for processed food industries. The Journal of Food Science and Technology 52 (12): 7561–7576.PubMed
14.
Zurück zum Zitat Poulsen, M.W., R.V. Hedegaard, J.M. Andersen, B. de Courten, S. Bügel, J. Nielsen, L.H. Skibsted, and L.O. Dragsted. 2013. Advanced glycation endproducts in food and their effects on health. Food and chemical toxicology: An international journal published for the British Industrial Biological Research Association 60: 10–37. Poulsen, M.W., R.V. Hedegaard, J.M. Andersen, B. de Courten, S. Bügel, J. Nielsen, L.H. Skibsted, and L.O. Dragsted. 2013. Advanced glycation endproducts in food and their effects on health. Food and chemical toxicology: An international journal published for the British Industrial Biological Research Association 60: 10–37.
15.
Zurück zum Zitat Zhang, Q., J.M. Ames, R.D. Smith, J.W. Baynes, and T.O. Metz. 2009. A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: Probing the pathogenesis of chronic disease. Journal of Proteome Research 8 (2): 754–769.PubMedPubMedCentral Zhang, Q., J.M. Ames, R.D. Smith, J.W. Baynes, and T.O. Metz. 2009. A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: Probing the pathogenesis of chronic disease. Journal of Proteome Research 8 (2): 754–769.PubMedPubMedCentral
16.
Zurück zum Zitat Singh, V.P., A. Bali, N. Singh, and A.S. Jaggi. 2014. Advanced glycation end products and diabetic complications. The Korean Journal of Physiology & Pharmacology 18 (1): 1–14. Singh, V.P., A. Bali, N. Singh, and A.S. Jaggi. 2014. Advanced glycation end products and diabetic complications. The Korean Journal of Physiology & Pharmacology 18 (1): 1–14.
17.
Zurück zum Zitat Henning, C., K. Liehr, M. Girndt, C. Ulrich, and M.A. Glomb. 2014. Extending the spectrum of α-dicarbonyl compounds in vivo. The Journal of biological chemistry 289 (41): 28676–28688.PubMedPubMedCentral Henning, C., K. Liehr, M. Girndt, C. Ulrich, and M.A. Glomb. 2014. Extending the spectrum of α-dicarbonyl compounds in vivo. The Journal of biological chemistry 289 (41): 28676–28688.PubMedPubMedCentral
18.
Zurück zum Zitat Brings, S., T. Fleming, M. Freichel, M.U. Muckenthaler, S. Herzig, and P.P. Nawroth. 2017. Dicarbonyls and advanced glycation end-products in the development of diabetic complications and targets for intervention. International Journal of Molecular Sciences 18 (5): 984.PubMedCentral Brings, S., T. Fleming, M. Freichel, M.U. Muckenthaler, S. Herzig, and P.P. Nawroth. 2017. Dicarbonyls and advanced glycation end-products in the development of diabetic complications and targets for intervention. International Journal of Molecular Sciences 18 (5): 984.PubMedCentral
19.
Zurück zum Zitat Thornalley, P.J. 2008. Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems–role in ageing and disease. Drug Metabolism and Drug Interactions 23 (1–2): 125–150.PubMedPubMedCentral Thornalley, P.J. 2008. Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems–role in ageing and disease. Drug Metabolism and Drug Interactions 23 (1–2): 125–150.PubMedPubMedCentral
20.
Zurück zum Zitat Rowan, S., E. Bejarano, and A. Taylor. 2018. Mechanistic targeting of advanced glycation end-products in age-related diseases. Biochimica et biophysica acta Molecular basis of disease 1864 (12): 3631–3643.PubMedPubMedCentral Rowan, S., E. Bejarano, and A. Taylor. 2018. Mechanistic targeting of advanced glycation end-products in age-related diseases. Biochimica et biophysica acta Molecular basis of disease 1864 (12): 3631–3643.PubMedPubMedCentral
21.
Zurück zum Zitat Guo, T., D. Zhang, Y. Zeng, T.Y. Huang, H. Xu, and Y. Zhao. 2020. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease. Molecular neurodegeneration 15 (1): 40.PubMedPubMedCentral Guo, T., D. Zhang, Y. Zeng, T.Y. Huang, H. Xu, and Y. Zhao. 2020. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease. Molecular neurodegeneration 15 (1): 40.PubMedPubMedCentral
22.
Zurück zum Zitat Chaudhuri, J., Y. Bains, S. Guha, A. Kahn, D. Hall, N. Bose, A. Gugliucci, and P. Kapahi. 2018. The role of advanced glycation end products in aging and metabolic diseases: Bridging association and causality. Cell Metabolism 28 (3): 337–352.PubMedPubMedCentral Chaudhuri, J., Y. Bains, S. Guha, A. Kahn, D. Hall, N. Bose, A. Gugliucci, and P. Kapahi. 2018. The role of advanced glycation end products in aging and metabolic diseases: Bridging association and causality. Cell Metabolism 28 (3): 337–352.PubMedPubMedCentral
23.
Zurück zum Zitat Fishman, S.L., H. Sonmez, C. Basman, V. Singh, and L. Poretsky. 2018. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: A review. Molecular Medicine 24 (1): 59.PubMedPubMedCentral Fishman, S.L., H. Sonmez, C. Basman, V. Singh, and L. Poretsky. 2018. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: A review. Molecular Medicine 24 (1): 59.PubMedPubMedCentral
24.
Zurück zum Zitat Otta, C., K. Jacobsb, E. Hauckec, A.N. Santos, T. Grunea, and A. Simm. 2014. Role of advanced glycation end products in cellular signalling. Redox Biology 2: 411–429. Otta, C., K. Jacobsb, E. Hauckec, A.N. Santos, T. Grunea, and A. Simm. 2014. Role of advanced glycation end products in cellular signalling. Redox Biology 2: 411–429.
25.
Zurück zum Zitat Iannuzzi, C., G. Irace, and I. Sirangelo. 2014. Differential effects of glycation on protein aggregation and amyloid formation. Frontiers in Molecular Biosciences 1: 9.PubMedPubMedCentral Iannuzzi, C., G. Irace, and I. Sirangelo. 2014. Differential effects of glycation on protein aggregation and amyloid formation. Frontiers in Molecular Biosciences 1: 9.PubMedPubMedCentral
26.
Zurück zum Zitat Quiñonez-Flores, C.M., S.A. González-Chávez, D. Del Río Nájera, and C. Pacheco-Tena. 2016. Oxidative stress relevance in the pathogenesis of the rheumatoid arthritis: A systematic review. BioMed Research International 2016: 6097417.PubMedPubMedCentral Quiñonez-Flores, C.M., S.A. González-Chávez, D. Del Río Nájera, and C. Pacheco-Tena. 2016. Oxidative stress relevance in the pathogenesis of the rheumatoid arthritis: A systematic review. BioMed Research International 2016: 6097417.PubMedPubMedCentral
27.
Zurück zum Zitat Phaniendra, A., D.B. Jestadi, and L. Periyasamy. 2015. Free radicals: Properties sources targets and their implication in various diseases. Indian journal of clinical biochemistry 30 (1): 11–26.PubMed Phaniendra, A., D.B. Jestadi, and L. Periyasamy. 2015. Free radicals: Properties sources targets and their implication in various diseases. Indian journal of clinical biochemistry 30 (1): 11–26.PubMed
28.
Zurück zum Zitat Filippin, L.I., R. Vercelino, N.P. Marroni, and R.M. Xavier. 2008. Redox signalling and the inflammatory response in rheumatoid arthritis. Clinical and experimental immunology 152 (3): 415–422.PubMedPubMedCentral Filippin, L.I., R. Vercelino, N.P. Marroni, and R.M. Xavier. 2008. Redox signalling and the inflammatory response in rheumatoid arthritis. Clinical and experimental immunology 152 (3): 415–422.PubMedPubMedCentral
29.
Zurück zum Zitat da Fonseca, L., V. Nunes-Souza, M. Goulart, and L.A. Rabelo. 2019. Oxidative stress in rheumatoid arthritis: What the future might hold regarding novel biomarkers and add-on therapies. Oxidative medicine and cellular longevity 2019: 7536805.PubMedPubMedCentral da Fonseca, L., V. Nunes-Souza, M. Goulart, and L.A. Rabelo. 2019. Oxidative stress in rheumatoid arthritis: What the future might hold regarding novel biomarkers and add-on therapies. Oxidative medicine and cellular longevity 2019: 7536805.PubMedPubMedCentral
30.
Zurück zum Zitat Wright, H. L., M. Lyon, E.A. Chapman, R.J. Moots, and S.W. Edwards. 2021. Rheumatoid arthritis synovial fluid neutrophils drive inflammation through production of chemokines reactive oxygen species and neutrophil extracellular traps. Frontiers in immunology 11: 584116. Wright, H. L., M. Lyon, E.A. Chapman, R.J. Moots, and S.W. Edwards. 2021. Rheumatoid arthritis synovial fluid neutrophils drive inflammation through production of chemokines reactive oxygen species and neutrophil extracellular traps. Frontiers in immunology 11: 584116.
31.
Zurück zum Zitat Butterfield, T.A., T.M. Best, and M.A. Merrick. 2006. The dual roles of neutrophils and macrophages in inflammation: A critical balance between tissue damage and repair. Journal of athletic training 41 (4): 457–465.PubMedPubMedCentral Butterfield, T.A., T.M. Best, and M.A. Merrick. 2006. The dual roles of neutrophils and macrophages in inflammation: A critical balance between tissue damage and repair. Journal of athletic training 41 (4): 457–465.PubMedPubMedCentral
32.
Zurück zum Zitat Selders, G.S., A.E. Fetz, M.Z. Radic, and G.L. Bowlin. 2017. An overview of the role of neutrophils in innate immunity, inflammation and host-biomaterial integration. Regenerative biomaterials 4 (1): 55–68.PubMedPubMedCentral Selders, G.S., A.E. Fetz, M.Z. Radic, and G.L. Bowlin. 2017. An overview of the role of neutrophils in innate immunity, inflammation and host-biomaterial integration. Regenerative biomaterials 4 (1): 55–68.PubMedPubMedCentral
33.
Zurück zum Zitat Delgado-Rizo, V., M.A. Martínez-Guzmán, L. Iñiguez-Gutierrez, A. García-Orozco, A. Alvarado-Navarro, and M. Fafutis-Morris. 2017. Neutrophil extracellular traps and its implications in inflammation: An overview. Frontiers in Immunology 8: 81.PubMedPubMedCentral Delgado-Rizo, V., M.A. Martínez-Guzmán, L. Iñiguez-Gutierrez, A. García-Orozco, A. Alvarado-Navarro, and M. Fafutis-Morris. 2017. Neutrophil extracellular traps and its implications in inflammation: An overview. Frontiers in Immunology 8: 81.PubMedPubMedCentral
34.
Zurück zum Zitat Fousert, E., R. Toes, and J. Desai. 2020. Neutrophil Extracellular Traps (NETs) Take the central stage in driving autoimmune responses. Cells 9 (4): 915.PubMedCentral Fousert, E., R. Toes, and J. Desai. 2020. Neutrophil Extracellular Traps (NETs) Take the central stage in driving autoimmune responses. Cells 9 (4): 915.PubMedCentral
35.
Zurück zum Zitat Vorobjeva, N.V., and B.V. Chernyak. 2020. NETosis: Molecular mechanisms role in physiology and pathology. Biochemistry Biokhimiia 85 (10): 1178–1190.PubMedPubMedCentral Vorobjeva, N.V., and B.V. Chernyak. 2020. NETosis: Molecular mechanisms role in physiology and pathology. Biochemistry Biokhimiia 85 (10): 1178–1190.PubMedPubMedCentral
36.
Zurück zum Zitat Metzler, K.D., C. Goosmann, A. Lubojemska, A. Zychlinsky, and V. Papayannopoulos. 2014. A myeloperoxidase-containing complex regulates neutrophil elastase release and actin dynamics during NETosis. Cell Reports 8 (3): 883–896.PubMed Metzler, K.D., C. Goosmann, A. Lubojemska, A. Zychlinsky, and V. Papayannopoulos. 2014. A myeloperoxidase-containing complex regulates neutrophil elastase release and actin dynamics during NETosis. Cell Reports 8 (3): 883–896.PubMed
37.
Zurück zum Zitat Sur Chowdhury, C., S. Giaglis, U.A. Walker, A. Buser, S. Hahn, and P. Hasler. 2014. Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: Analysis of underlying signal transduction pathways and potential diagnostic utility. Arthritis research & therapy 16 (3): R122. Sur Chowdhury, C., S. Giaglis, U.A. Walker, A. Buser, S. Hahn, and P. Hasler. 2014. Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: Analysis of underlying signal transduction pathways and potential diagnostic utility. Arthritis research & therapy 16 (3): R122.
38.
Zurück zum Zitat Heidari, F., S. Rabizadeh, A. Rajab, F. Heidari, M. Mouodi, H. Mirmiranpour, A. Esteghamati, and M. Nakhjavani. 2020. Advanced glycation end-products and advanced oxidation protein products levels are correlates of duration of type 2 diabetes. Life sciences 260: 118422. Heidari, F., S. Rabizadeh, A. Rajab, F. Heidari, M. Mouodi, H. Mirmiranpour, A. Esteghamati, and M. Nakhjavani. 2020. Advanced glycation end-products and advanced oxidation protein products levels are correlates of duration of type 2 diabetes. Life sciences 260: 118422.
39.
Zurück zum Zitat Khojah, H.M., S. Ahmed, M.S. Abdel-Rahman, and A.B. Hamza. 2016. Reactive oxygen and nitrogen species in patients with rheumatoid arthritis as potential biomarkers for disease activity and the role of antioxidants. Free radical biology & medicine 97: 285–291. Khojah, H.M., S. Ahmed, M.S. Abdel-Rahman, and A.B. Hamza. 2016. Reactive oxygen and nitrogen species in patients with rheumatoid arthritis as potential biomarkers for disease activity and the role of antioxidants. Free radical biology & medicine 97: 285–291.
40.
Zurück zum Zitat Yan, S.F., S.D. Yan, R. Ramasamy, and A.M. Schmidt. 2009. Tempering the wrath of RAGE: An emerging therapeutic strategy against diabetic complications neurodegeneration and inflammation. Annals of Medicine 41 (6): 408–422.PubMed Yan, S.F., S.D. Yan, R. Ramasamy, and A.M. Schmidt. 2009. Tempering the wrath of RAGE: An emerging therapeutic strategy against diabetic complications neurodegeneration and inflammation. Annals of Medicine 41 (6): 408–422.PubMed
41.
Zurück zum Zitat Xue, J., V. Rai, D. Singer, S. Chabierski, J. Xie, S. Reverdatto, D.S. Burz, A.M. Schmidt, R. Hoffmann, and A. Shekhtman. 2011. Advanced glycation end product recognition by the receptor for AGEs. Structure 19 (5): 722–732.PubMedPubMedCentral Xue, J., V. Rai, D. Singer, S. Chabierski, J. Xie, S. Reverdatto, D.S. Burz, A.M. Schmidt, R. Hoffmann, and A. Shekhtman. 2011. Advanced glycation end product recognition by the receptor for AGEs. Structure 19 (5): 722–732.PubMedPubMedCentral
43.
Zurück zum Zitat Chuah, Y.K., R. Basir, H. Talib, T.H. Tie, and N. Nordin. 2013. Receptor for advanced glycation end products and its involvement in inflammatory diseases. International Journal of Inflammation 2013: 403460. Chuah, Y.K., R. Basir, H. Talib, T.H. Tie, and N. Nordin. 2013. Receptor for advanced glycation end products and its involvement in inflammatory diseases. International Journal of Inflammation 2013: 403460.
45.
Zurück zum Zitat Perrone, A., A. Giovino, J. Benny, and F. Martinelli. 2020. Advanced glycation end products (AGEs): Biochemistry signaling analytical methods and epigenetic effects. Oxidative medicine and cellular longevity 2020: 3818196.PubMedPubMedCentral Perrone, A., A. Giovino, J. Benny, and F. Martinelli. 2020. Advanced glycation end products (AGEs): Biochemistry signaling analytical methods and epigenetic effects. Oxidative medicine and cellular longevity 2020: 3818196.PubMedPubMedCentral
46.
Zurück zum Zitat Yap, H.Y., S.Z. Tee, M.M. Wong, S.K. Chow, S.C. Peh, and S.Y. Teow. 2018. Pathogenic role of immune cells in rheumatoid arthritis: Implications in clinical treatment and biomarker development. Cells 7 (10): 161.PubMedCentral Yap, H.Y., S.Z. Tee, M.M. Wong, S.K. Chow, S.C. Peh, and S.Y. Teow. 2018. Pathogenic role of immune cells in rheumatoid arthritis: Implications in clinical treatment and biomarker development. Cells 7 (10): 161.PubMedCentral
47.
Zurück zum Zitat Chen, J., J. Jing, S. Yu, M. Song, H. Tan, B. Cui, and L. Huang. 2016. Advanced glycation endproducts induce apoptosis of endothelial progenitor cells by activating receptor RAGE and NADPH oxidase/JNK signaling axis. American journal of translational research 8 (5): 2169–2178.PubMedPubMedCentral Chen, J., J. Jing, S. Yu, M. Song, H. Tan, B. Cui, and L. Huang. 2016. Advanced glycation endproducts induce apoptosis of endothelial progenitor cells by activating receptor RAGE and NADPH oxidase/JNK signaling axis. American journal of translational research 8 (5): 2169–2178.PubMedPubMedCentral
48.
Zurück zum Zitat Tarafdar, A., and G. Pula. 2018. The role of NADPH oxidases and oxidative stress in neurodegenerative disorders. International journal of molecular sciences 19 (12): 3824.PubMedCentral Tarafdar, A., and G. Pula. 2018. The role of NADPH oxidases and oxidative stress in neurodegenerative disorders. International journal of molecular sciences 19 (12): 3824.PubMedCentral
49.
Zurück zum Zitat Wang, X., S. Yu, C.Y. Wang, Y. Wang, H.X. Liu, Y. Cui, and L.D. Zhang. 2015. Advanced glycation end products induce oxidative stress and mitochondrial dysfunction in SH-SY5Y cells. In vitro cellular & developmental biology-Animal 51 (2): 204–209. Wang, X., S. Yu, C.Y. Wang, Y. Wang, H.X. Liu, Y. Cui, and L.D. Zhang. 2015. Advanced glycation end products induce oxidative stress and mitochondrial dysfunction in SH-SY5Y cells. In vitro cellular & developmental biology-Animal 51 (2): 204–209.
50.
Zurück zum Zitat Pérez-Torres, I., L. Manzano-Pech, M.E. Rubio-Ruíz, M.E. Soto, and V. Guarner-Lans. 2020. Nitrosative stress and its association with cardiometabolic disorders. Molecules (Basel, Switzerland) 25 (11): 2555. Pérez-Torres, I., L. Manzano-Pech, M.E. Rubio-Ruíz, M.E. Soto, and V. Guarner-Lans. 2020. Nitrosative stress and its association with cardiometabolic disorders. Molecules (Basel, Switzerland) 25 (11): 2555.
51.
Zurück zum Zitat Giovino, A., J. Benny, and F. Martinelli. 2020. Advanced glycation end products (AGEs): Biochemistry, signaling, analytical methods, and epigenetic effects. Oxidative Medicine and Cellular Longevity 2020: 18. Giovino, A., J. Benny, and F. Martinelli. 2020. Advanced glycation end products (AGEs): Biochemistry, signaling, analytical methods, and epigenetic effects. Oxidative Medicine and Cellular Longevity 2020: 18.
52.
Zurück zum Zitat Semchyshyn, H.M. 2014. Reactive carbonyl species in vivo: generation and dual biological effects. The Scientific World Journal 2014: 417842. Semchyshyn, H.M. 2014. Reactive carbonyl species in vivo: generation and dual biological effects. The Scientific World Journal 2014: 417842.
53.
Zurück zum Zitat Hansen, F., F. Galland, F. Lirio, D.F. de Souza, C. Da Ré, R.F. Pacheco, A.F. Vizuete, A. Quincozes-Santos, M.C. Leite, and C.A. Gonçalves. 2017. Methylglyoxal induces changes in the glyoxalase system and impairs glutamate uptake activity in primary astrocytes. Oxidative medicine and cellular longevity 2017: 9574201.PubMedPubMedCentral Hansen, F., F. Galland, F. Lirio, D.F. de Souza, C. Da Ré, R.F. Pacheco, A.F. Vizuete, A. Quincozes-Santos, M.C. Leite, and C.A. Gonçalves. 2017. Methylglyoxal induces changes in the glyoxalase system and impairs glutamate uptake activity in primary astrocytes. Oxidative medicine and cellular longevity 2017: 9574201.PubMedPubMedCentral
54.
Zurück zum Zitat Knani, I., H. Bouzidi, S. Zrour, N. Bergaoui, M. Hammami, and M. Kerkeni. 2018. Methylglyoxal: A relevant marker of disease activity in patients with rheumatoid arthritis. Disease Markers 2018: 8735926.PubMedPubMedCentral Knani, I., H. Bouzidi, S. Zrour, N. Bergaoui, M. Hammami, and M. Kerkeni. 2018. Methylglyoxal: A relevant marker of disease activity in patients with rheumatoid arthritis. Disease Markers 2018: 8735926.PubMedPubMedCentral
55.
Zurück zum Zitat Schalkwijk, C.G., and C. Stehouwer. 2020. Methylglyoxal a highly reactive dicarbonyl compound in diabetes its vascular complications and other age-related diseases. Physiological reviews 100 (1): 407–461.PubMed Schalkwijk, C.G., and C. Stehouwer. 2020. Methylglyoxal a highly reactive dicarbonyl compound in diabetes its vascular complications and other age-related diseases. Physiological reviews 100 (1): 407–461.PubMed
56.
Zurück zum Zitat Kender, Z., P. Torzsa, K.V. Grolmusz, A. Patócs, A. Lichthammer, M. Veresné Bálint, K. Rácz, and P. Reismann. 2012. A metilglioxál metabolizmus szerepe 2-es típusú cukorbetegségben és szövődményeiben [The role of methylglyoxal metabolism in type-2 diabetes and its complications]. Orvosi hetilap 153 (15): 574–585.PubMed Kender, Z., P. Torzsa, K.V. Grolmusz, A. Patócs, A. Lichthammer, M. Veresné Bálint, K. Rácz, and P. Reismann. 2012. A metilglioxál metabolizmus szerepe 2-es típusú cukorbetegségben és szövődményeiben [The role of methylglyoxal metabolism in type-2 diabetes and its complications]. Orvosi hetilap 153 (15): 574–585.PubMed
57.
Zurück zum Zitat Pullerits, R., M. Bokarewa, L. Dahlberg, and A. Tarkowski. 2005. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Research Therapy 7 (4): R817–R824.PubMedPubMedCentral Pullerits, R., M. Bokarewa, L. Dahlberg, and A. Tarkowski. 2005. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Research Therapy 7 (4): R817–R824.PubMedPubMedCentral
58.
Zurück zum Zitat Lund, T., A. Svindland, M. Pepaj, A.B. Jensen, J.P. Berg, B. Kilhovd, and K.F. Hanssen. 2011. Fibrinogen may be an important target for methylglyoxal-derived AGE modification in elastic arteries of humans. Diabetes & vascular disease research 8 (4): 284–294. Lund, T., A. Svindland, M. Pepaj, A.B. Jensen, J.P. Berg, B. Kilhovd, and K.F. Hanssen. 2011. Fibrinogen may be an important target for methylglyoxal-derived AGE modification in elastic arteries of humans. Diabetes & vascular disease research 8 (4): 284–294.
59.
Zurück zum Zitat Shaw, J.N., J.W. Baynes, and S.R. Thorpe. 2002. N epsilon-(carboxymethyl) lysine (CML) as a biomarker of oxidative stress in long-lived tissue proteins. Methods in Molecular Biology 186: 129–137.PubMed Shaw, J.N., J.W. Baynes, and S.R. Thorpe. 2002. N epsilon-(carboxymethyl) lysine (CML) as a biomarker of oxidative stress in long-lived tissue proteins. Methods in Molecular Biology 186: 129–137.PubMed
60.
Zurück zum Zitat Drinda, S., S. Franke, C.C. Canet, P. Petrow, R. Bräuer, C. Hüttich, G. Stein, and G. Hein. 2002. Identification of the advanced glycation end products N(epsilon)-carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 61 (6): 488–492.PubMedPubMedCentral Drinda, S., S. Franke, C.C. Canet, P. Petrow, R. Bräuer, C. Hüttich, G. Stein, and G. Hein. 2002. Identification of the advanced glycation end products N(epsilon)-carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 61 (6): 488–492.PubMedPubMedCentral
61.
Zurück zum Zitat Knani, I., H. Bouzidi, S. Zrour, N. Bergaoui, M. Hammami, and M. Kerkeni. 2018. Increased serum concentrations of Nɛ-carboxymethyllysine are related to the presence and the severity of rheumatoid arthritis. Annals of clinical biochemistry 55 (4): 430–436.PubMed Knani, I., H. Bouzidi, S. Zrour, N. Bergaoui, M. Hammami, and M. Kerkeni. 2018. Increased serum concentrations of Nɛ-carboxymethyllysine are related to the presence and the severity of rheumatoid arthritis. Annals of clinical biochemistry 55 (4): 430–436.PubMed
62.
Zurück zum Zitat Sternberg, Z., C. Hennies, D. Sternberg, P. Wang, P. Kinkel, D. Hojnacki, B. Weinstock-Guttmann, and F. Munschauer. 2010. Diagnostic potential of plasma carboxymethyllysine and carboxyethyllysine in multiple sclerosis. Journal of Neuroinflammation 7: 72.PubMedPubMedCentral Sternberg, Z., C. Hennies, D. Sternberg, P. Wang, P. Kinkel, D. Hojnacki, B. Weinstock-Guttmann, and F. Munschauer. 2010. Diagnostic potential of plasma carboxymethyllysine and carboxyethyllysine in multiple sclerosis. Journal of Neuroinflammation 7: 72.PubMedPubMedCentral
63.
Zurück zum Zitat Kinoshita, S., K. Mera, H. Ichikawa, S. Shimasaki, M. Nagai, Y. Taga, K. Iijima, S. Hattori, Y. Fujiwara, J.I. Shirakawa, and R. Nagai. 2019. Nω -(carboxymethyl)arginine is one of the dominant advanced glycation end products in glycated collagens and mouse tissues. Oxidative Medicine and Cellular Longevity 2019: 9073451.PubMedPubMedCentral Kinoshita, S., K. Mera, H. Ichikawa, S. Shimasaki, M. Nagai, Y. Taga, K. Iijima, S. Hattori, Y. Fujiwara, J.I. Shirakawa, and R. Nagai. 2019. Nω -(carboxymethyl)arginine is one of the dominant advanced glycation end products in glycated collagens and mouse tissues. Oxidative Medicine and Cellular Longevity 2019: 9073451.PubMedPubMedCentral
64.
Zurück zum Zitat Ricard-Blum, S. 2011. The collagen family. Cold Spring Harbor Perspectives in Biology 3 (1): a004978. Ricard-Blum, S. 2011. The collagen family. Cold Spring Harbor Perspectives in Biology 3 (1): a004978.
65.
Zurück zum Zitat Reigle, K.L., G. Di Lullo, K.R. Turner, J.A. Last, I. Chervoneva, D.E. Birk, J.L. Funderburgh, E. Elrod, M.W. Germann, C. Surber, R.D. Sanderson, and J.D. San Antonio. 2008. Non-enzymatic glycation of type I collagen diminishes collagen-proteoglycan binding and weakens cell adhesion. Journal of Cellular Biochemistry 104 (5): 1684–1698.PubMedPubMedCentral Reigle, K.L., G. Di Lullo, K.R. Turner, J.A. Last, I. Chervoneva, D.E. Birk, J.L. Funderburgh, E. Elrod, M.W. Germann, C. Surber, R.D. Sanderson, and J.D. San Antonio. 2008. Non-enzymatic glycation of type I collagen diminishes collagen-proteoglycan binding and weakens cell adhesion. Journal of Cellular Biochemistry 104 (5): 1684–1698.PubMedPubMedCentral
66.
Zurück zum Zitat Braun, M., H. Hulejová, J. Gatterová, M. Filková, A. Pavelková, O. Sléglová, N. Kaspříková, J. Vencovský, K. Pavelka, and L. Senolt. 2012. Pentosidine, an advanced glycation end-product, may reflect clinical and morphological features of hand osteoarthritis. The Open Rheumatology Journal 6: 64–69.PubMedPubMedCentral Braun, M., H. Hulejová, J. Gatterová, M. Filková, A. Pavelková, O. Sléglová, N. Kaspříková, J. Vencovský, K. Pavelka, and L. Senolt. 2012. Pentosidine, an advanced glycation end-product, may reflect clinical and morphological features of hand osteoarthritis. The Open Rheumatology Journal 6: 64–69.PubMedPubMedCentral
67.
Zurück zum Zitat Takahashi, M., M. Suzuki, K. Kushida, S. Miyamoto, and T. Inoue. 1997. Relationship between pentosidine levels in serum and urine and activity in rheumatoid arthritis. The British Journal of Rheumatology 36 (6): 637–642.PubMed Takahashi, M., M. Suzuki, K. Kushida, S. Miyamoto, and T. Inoue. 1997. Relationship between pentosidine levels in serum and urine and activity in rheumatoid arthritis. The British Journal of Rheumatology 36 (6): 637–642.PubMed
68.
Zurück zum Zitat Miyata, T., N. Ishiguro, Y. Yasuda, T. Ito, M. Nangaku, H. Iwata, and K. Kurokawa. 1998. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochemical and biophysical research communications 244 (1): 45–49.PubMed Miyata, T., N. Ishiguro, Y. Yasuda, T. Ito, M. Nangaku, H. Iwata, and K. Kurokawa. 1998. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochemical and biophysical research communications 244 (1): 45–49.PubMed
69.
Zurück zum Zitat Chen, J.R., M. Takahashi, M. Suzuki, K. Kushida, S. Miyamoto, and T. Inoue. 1999. Pentosidine in synovial fluid in osteoarthritis and rheumatoid arthritis: Relationship with disease activity in rheumatoid arthritis. Journal of Rheumatology 25 (12): 2440–2444. Chen, J.R., M. Takahashi, M. Suzuki, K. Kushida, S. Miyamoto, and T. Inoue. 1999. Pentosidine in synovial fluid in osteoarthritis and rheumatoid arthritis: Relationship with disease activity in rheumatoid arthritis. Journal of Rheumatology 25 (12): 2440–2444.
70.
Zurück zum Zitat Neelofar, K., and J. Ahmad. 2015. Amadori albumin in diabetic nephropathy. Indian Journal of Endocrinology and Metabolism 19 (1): 39–46.PubMedPubMedCentral Neelofar, K., and J. Ahmad. 2015. Amadori albumin in diabetic nephropathy. Indian Journal of Endocrinology and Metabolism 19 (1): 39–46.PubMedPubMedCentral
71.
Zurück zum Zitat Arif, Z., M.Y. Arfat, J. Ahmad, A. Zaman, S.N. Islam, and M.A. Khan. 2015. Relevance of nitroxidation of albumin in rheumatoid arthritis: A biochemical and clinical study. Journal of Clinical & Cellular Immunology 6: 2. Arif, Z., M.Y. Arfat, J. Ahmad, A. Zaman, S.N. Islam, and M.A. Khan. 2015. Relevance of nitroxidation of albumin in rheumatoid arthritis: A biochemical and clinical study. Journal of Clinical & Cellular Immunology 6: 2.
72.
Zurück zum Zitat Tarannum, A., Z. Arif, K. Alam, S. Ahmad, and M. Uddin. 2019. Nitroxidized-albumin advanced glycation end product and rheumatoid arthritis. Archives of Rheumatology 34 (4): 461–475.PubMedPubMedCentral Tarannum, A., Z. Arif, K. Alam, S. Ahmad, and M. Uddin. 2019. Nitroxidized-albumin advanced glycation end product and rheumatoid arthritis. Archives of Rheumatology 34 (4): 461–475.PubMedPubMedCentral
73.
Zurück zum Zitat Baret, P., F. Le Sage, C. Planesse, O. Meilhac, A. Devin, E. Bourdon, and P. Rondeau. 2017. Glycated human albumin alters mitochondrial respiration in preadipocyte 3T3-L1 cells. BioFactors (Oxford England) 43 (4): 577–592. Baret, P., F. Le Sage, C. Planesse, O. Meilhac, A. Devin, E. Bourdon, and P. Rondeau. 2017. Glycated human albumin alters mitochondrial respiration in preadipocyte 3T3-L1 cells. BioFactors (Oxford England) 43 (4): 577–592.
74.
Zurück zum Zitat Panezai, J., M. Altamash, P.E. Engstrӧm, and A. Larsson. 2020. Association of glycated proteins with inflammatory proteins and periodontal disease parameters. Journal of Diabetes Research 2020: 6450742.PubMedPubMedCentral Panezai, J., M. Altamash, P.E. Engstrӧm, and A. Larsson. 2020. Association of glycated proteins with inflammatory proteins and periodontal disease parameters. Journal of Diabetes Research 2020: 6450742.PubMedPubMedCentral
75.
Zurück zum Zitat Babu, N.P., Z. Bobby, N. Selvaraj, and B.N. Harish. 2006. Increased fructosamine in non-diabetic rheumatoid arthritis patients: Role of lipid peroxides and glutathione. Clinical Chemistry and Laboratory Medicine 44 (7): 848–852.PubMed Babu, N.P., Z. Bobby, N. Selvaraj, and B.N. Harish. 2006. Increased fructosamine in non-diabetic rheumatoid arthritis patients: Role of lipid peroxides and glutathione. Clinical Chemistry and Laboratory Medicine 44 (7): 848–852.PubMed
76.
Zurück zum Zitat Gkogkolou, P., and M. Böhm. 2012. Advanced glycation end products: Key players in skin aging? Dermatoendocrinology 4 (3): 259–270. Gkogkolou, P., and M. Böhm. 2012. Advanced glycation end products: Key players in skin aging? Dermatoendocrinology 4 (3): 259–270.
77.
Zurück zum Zitat Monnier, V.M. 2006. The fructosamine 3-kinase knockout mouse: A tool for testing the glycation hypothesis of intracellular protein damage in diabetes and aging. Biochemical Journal 399 (2): e11–e13.PubMedCentral Monnier, V.M. 2006. The fructosamine 3-kinase knockout mouse: A tool for testing the glycation hypothesis of intracellular protein damage in diabetes and aging. Biochemical Journal 399 (2): e11–e13.PubMedCentral
78.
Zurück zum Zitat Legrand, C., U. Ahmed, A. Anwar, K. Rajpoot, S. Pasha, C. Lambert, R.K. Davidson, I.M. Clark, P.J. Thornalley, Y. Henrotin, and N. Rabbani. 2018. Glycation marker glucosepane increases with the progression of osteoarthritis and correlates with morphological and functional changes of cartilage in vivo. Arthritis Research & Therapy 20: 131. Legrand, C., U. Ahmed, A. Anwar, K. Rajpoot, S. Pasha, C. Lambert, R.K. Davidson, I.M. Clark, P.J. Thornalley, Y. Henrotin, and N. Rabbani. 2018. Glycation marker glucosepane increases with the progression of osteoarthritis and correlates with morphological and functional changes of cartilage in vivo. Arthritis Research & Therapy 20: 131.
79.
Zurück zum Zitat Monnier, V.M., W. Sun, D.R. Sell, X. Fan, I. Nemet, and S. Genuth. 2014. Glucosepane: A poorly understood advanced glycation end product of growing importance for diabetes and its complications. Clinical Chemistry and Laboratory Medicine 52 (1): 21–32.PubMedPubMedCentral Monnier, V.M., W. Sun, D.R. Sell, X. Fan, I. Nemet, and S. Genuth. 2014. Glucosepane: A poorly understood advanced glycation end product of growing importance for diabetes and its complications. Clinical Chemistry and Laboratory Medicine 52 (1): 21–32.PubMedPubMedCentral
80.
Zurück zum Zitat Genuth, S., W. Sun, P. Cleary, X. Gao, D.R. Sell, J. Lachin, and V.M. Monnier. 2015. Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes. Diabetes 64 (1): 266–278.PubMed Genuth, S., W. Sun, P. Cleary, X. Gao, D.R. Sell, J. Lachin, and V.M. Monnier. 2015. Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes. Diabetes 64 (1): 266–278.PubMed
81.
Zurück zum Zitat Tai, A.W., and M.M. Newkirk. 2000. An autoantibody targeting glycated IgG is associated with elevated serum immune complexes in rheumatoid arthritis (RA). Clinical and Experimental Immunology 120 (1): 188–193.PubMedPubMedCentral Tai, A.W., and M.M. Newkirk. 2000. An autoantibody targeting glycated IgG is associated with elevated serum immune complexes in rheumatoid arthritis (RA). Clinical and Experimental Immunology 120 (1): 188–193.PubMedPubMedCentral
82.
Zurück zum Zitat Newkirk, M.M., R. Goldbach-Mansky, J. Lee, J. Hoxworth, A. McCoy, C. Yarboro, J. Klippel, and H.S. El-Gabalawy. 2003. Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis. Arthritis Research & Therapy 5 (2): R82–R90. Newkirk, M.M., R. Goldbach-Mansky, J. Lee, J. Hoxworth, A. McCoy, C. Yarboro, J. Klippel, and H.S. El-Gabalawy. 2003. Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis. Arthritis Research & Therapy 5 (2): R82–R90.
83.
Zurück zum Zitat Newkirk, M.M., K. LePage, T. Niwa, and L. Rubin. 1998. Advanced glycation endproducts (AGE) on IgG, a target for circulating antibodies in North American Indians with rheumatoid arthritis (RA). Cellular and molecular biology 44 (7): 1129–1138.PubMed Newkirk, M.M., K. LePage, T. Niwa, and L. Rubin. 1998. Advanced glycation endproducts (AGE) on IgG, a target for circulating antibodies in North American Indians with rheumatoid arthritis (RA). Cellular and molecular biology 44 (7): 1129–1138.PubMed
84.
Zurück zum Zitat Byun, K., Y. Yoo, M. Son, J. Lee, G.B. Jeong, Y.M. Park, G.H. Salekdeh, and B. Lee. 2017. Advanced glycation end-products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases. Pharmacology & Therapeutics 177: 44–55. Byun, K., Y. Yoo, M. Son, J. Lee, G.B. Jeong, Y.M. Park, G.H. Salekdeh, and B. Lee. 2017. Advanced glycation end-products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases. Pharmacology & Therapeutics 177: 44–55.
85.
Zurück zum Zitat Yamin, G., K. Ono, M. Inayathullah, and D.B. Teplow. 2008. Amyloid beta-protein assembly as a therapeutic target of Alzheimer’s disease. Current Pharmaceutical Design 14 (30): 3231–3246.PubMedPubMedCentral Yamin, G., K. Ono, M. Inayathullah, and D.B. Teplow. 2008. Amyloid beta-protein assembly as a therapeutic target of Alzheimer’s disease. Current Pharmaceutical Design 14 (30): 3231–3246.PubMedPubMedCentral
86.
Zurück zum Zitat O’Brien, R.J., and P.C. Wong. 2011. Amyloid precursor protein processing and Alzheimer’s disease. Annual Review of Neuroscience 34: 185–204.PubMedPubMedCentral O’Brien, R.J., and P.C. Wong. 2011. Amyloid precursor protein processing and Alzheimer’s disease. Annual Review of Neuroscience 34: 185–204.PubMedPubMedCentral
87.
Zurück zum Zitat Ferraccioli, G., A. Carbonella, E. Gremese, and S. Alivernini. 2012. Rheumatoid arthritis and Alzheimer’s disease: Genetic and epigenetic links in inflammatory regulation. Discovery Medicine 14 (79): 379–388.PubMed Ferraccioli, G., A. Carbonella, E. Gremese, and S. Alivernini. 2012. Rheumatoid arthritis and Alzheimer’s disease: Genetic and epigenetic links in inflammatory regulation. Discovery Medicine 14 (79): 379–388.PubMed
88.
Zurück zum Zitat Huang, Y.M., X.Z. Hong, J. Shen, L.J. Geng, Y.H. Pan, W. Ling, and H.L. Zhao. 2020. Amyloids in site-specific autoimmune reactions and inflammatory responses. Frontiers in Immunology 10: 2980.PubMedPubMedCentral Huang, Y.M., X.Z. Hong, J. Shen, L.J. Geng, Y.H. Pan, W. Ling, and H.L. Zhao. 2020. Amyloids in site-specific autoimmune reactions and inflammatory responses. Frontiers in Immunology 10: 2980.PubMedPubMedCentral
89.
Zurück zum Zitat Tang, D., R. Kang, H.J. Zeh, and M.T. Lotze. 2010. High-mobility group box 1 and cancer. Biochimica et Biophysica Acta 1799 (1–2): 131–140.PubMedPubMedCentral Tang, D., R. Kang, H.J. Zeh, and M.T. Lotze. 2010. High-mobility group box 1 and cancer. Biochimica et Biophysica Acta 1799 (1–2): 131–140.PubMedPubMedCentral
90.
Zurück zum Zitat Andersson, U., and K.J. Tracey. 2011. HMGB1 is a therapeutic target for sterile inflammation and infection. Annual Review of Immunology 29: 139–162.PubMedPubMedCentral Andersson, U., and K.J. Tracey. 2011. HMGB1 is a therapeutic target for sterile inflammation and infection. Annual Review of Immunology 29: 139–162.PubMedPubMedCentral
91.
Zurück zum Zitat Weber, D.J., Y.M. Allette, D.S. Wilkes, and F.A. White. 2015. The HMGB1-RAGE inflammatory pathway: Implications for brain injury-induced pulmonary dysfunction. Antioxidants & Redox Signaling 23 (17): 1316–1328. Weber, D.J., Y.M. Allette, D.S. Wilkes, and F.A. White. 2015. The HMGB1-RAGE inflammatory pathway: Implications for brain injury-induced pulmonary dysfunction. Antioxidants & Redox Signaling 23 (17): 1316–1328.
92.
Zurück zum Zitat Sun, X.H., Y. Liu, Y. Han, and J. Wang. 2016. Expression and significance of high-mobility group protein B1 (HMGB1) and the receptor for advanced glycation end-product (RAGE) in knee osteoarthritis. Medical Science Monitor 22: 2105–2112.PubMedPubMedCentral Sun, X.H., Y. Liu, Y. Han, and J. Wang. 2016. Expression and significance of high-mobility group protein B1 (HMGB1) and the receptor for advanced glycation end-product (RAGE) in knee osteoarthritis. Medical Science Monitor 22: 2105–2112.PubMedPubMedCentral
93.
Zurück zum Zitat Qian, B., H. Huang, M. Cheng, T. Qin, T. Chen, and J. Zhao. 2020. Mechanism of HMGB1-RAGE in Kawasaki disease with coronary artery injury. European Journal of Medical Research 25 (1): 8.PubMedPubMedCentral Qian, B., H. Huang, M. Cheng, T. Qin, T. Chen, and J. Zhao. 2020. Mechanism of HMGB1-RAGE in Kawasaki disease with coronary artery injury. European Journal of Medical Research 25 (1): 8.PubMedPubMedCentral
94.
Zurück zum Zitat Tang, D., R. Kang, H.J. Zeh, and M.T. Lotze. 2011. High-mobility group box 1 oxidative stress and disease. Antioxidants & redox signaling 14 (7): 1315–1335. Tang, D., R. Kang, H.J. Zeh, and M.T. Lotze. 2011. High-mobility group box 1 oxidative stress and disease. Antioxidants & redox signaling 14 (7): 1315–1335.
95.
Zurück zum Zitat Zhu, X.M., Y.M. Yao, H.P. Liang, S. Xu, N. Dong, Y. Yu, and Z.Y. Sheng. 2009. The effect of high mobility group box-1 protein on splenic dendritic cell maturation in rats. Journal of interferon & cytokine research 29 (10): 677–686. Zhu, X.M., Y.M. Yao, H.P. Liang, S. Xu, N. Dong, Y. Yu, and Z.Y. Sheng. 2009. The effect of high mobility group box-1 protein on splenic dendritic cell maturation in rats. Journal of interferon & cytokine research 29 (10): 677–686.
96.
Zurück zum Zitat Yoshino, S., E. Sasatomi, and M. Ohsawa. 2000. Bacterial lipopolysaccharide acts as an adjuvant to induce autoimmune arthritis in mice. Immunology 99 (4): 607–614.PubMedPubMedCentral Yoshino, S., E. Sasatomi, and M. Ohsawa. 2000. Bacterial lipopolysaccharide acts as an adjuvant to induce autoimmune arthritis in mice. Immunology 99 (4): 607–614.PubMedPubMedCentral
97.
Zurück zum Zitat Fang, W., D. Bi, R. Zheng, N. Cai, H. Xu, R. Zhou, J. Lu, M. Wan, and X. Xu. 2017. Identification and activation of TLR4-mediated signalling pathways by alginate-derived guluronate oligosaccharide in RAW264.7 macrophages. Scientific Reports 7 (1): 1663. Fang, W., D. Bi, R. Zheng, N. Cai, H. Xu, R. Zhou, J. Lu, M. Wan, and X. Xu. 2017. Identification and activation of TLR4-mediated signalling pathways by alginate-derived guluronate oligosaccharide in RAW264.7 macrophages. Scientific Reports 7 (1): 1663.
98.
Zurück zum Zitat Wahamaa, H., H. Schierbeck, H.S. Hreggvidsdottir, K. Palmblad, A.C. Aveberger, U. Andersson, and H.E. Harris. 2011. High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. Arthritis research & therapy 13 (4): R136. Wahamaa, H., H. Schierbeck, H.S. Hreggvidsdottir, K. Palmblad, A.C. Aveberger, U. Andersson, and H.E. Harris. 2011. High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. Arthritis research & therapy 13 (4): R136.
99.
Zurück zum Zitat He, Z.W., Y.H. Qin, Z.W. Wang, Y. Chen, Q. Shen, and S.M. Dai. 2013. HMGB1 acts in synergy with lipopolysaccharide in activating rheumatoid synovial fibroblasts via p38 MAPK and NF-κB signaling pathways. Mediators of Inflammation 2013: 596716. He, Z.W., Y.H. Qin, Z.W. Wang, Y. Chen, Q. Shen, and S.M. Dai. 2013. HMGB1 acts in synergy with lipopolysaccharide in activating rheumatoid synovial fibroblasts via p38 MAPK and NF-κB signaling pathways. Mediators of Inflammation 2013: 596716.
100.
Zurück zum Zitat Bednarczyk, M., H. Stege, S. Grabbe, and M. Bros. 2020. β2 Integrins-multi-functional leukocyte receptors in health and disease. International Journal of Molecular Sciences 21 (4): 1402.PubMedCentral Bednarczyk, M., H. Stege, S. Grabbe, and M. Bros. 2020. β2 Integrins-multi-functional leukocyte receptors in health and disease. International Journal of Molecular Sciences 21 (4): 1402.PubMedCentral
101.
Zurück zum Zitat Schittenhelm, L., C.M. Hilkens, and V.L. Morrison. 2017. β2 integrins as regulators of dendritic cell monocyte and macrophage function. Frontiers in Immunology 8: 1866.PubMedPubMedCentral Schittenhelm, L., C.M. Hilkens, and V.L. Morrison. 2017. β2 integrins as regulators of dendritic cell monocyte and macrophage function. Frontiers in Immunology 8: 1866.PubMedPubMedCentral
102.
Zurück zum Zitat Kassaar, O., M. Pereira Morais, S. Xu, E.L. Adam, R.C. Chamberlain, B. Jenkins, T.D. James, P.T. Francis, S. Ward, R.J. Williams, and J. van den Elsen. 2017. Macrophage migration inhibitory factor is subjected to glucose modification and oxidation in Alzheimer’s disease. Scientific Reports 7: 42874.PubMedPubMedCentral Kassaar, O., M. Pereira Morais, S. Xu, E.L. Adam, R.C. Chamberlain, B. Jenkins, T.D. James, P.T. Francis, S. Ward, R.J. Williams, and J. van den Elsen. 2017. Macrophage migration inhibitory factor is subjected to glucose modification and oxidation in Alzheimer’s disease. Scientific Reports 7: 42874.PubMedPubMedCentral
103.
Zurück zum Zitat Donato, R., B.R. Cannon, G. Sorci, F. Riuzzi, K. Hsu, D.J. Weber, and C.L. Geczy. 2013. Functions of S100 proteins. Current Molecular Medicine 13 (1): 24–57.PubMedPubMedCentral Donato, R., B.R. Cannon, G. Sorci, F. Riuzzi, K. Hsu, D.J. Weber, and C.L. Geczy. 2013. Functions of S100 proteins. Current Molecular Medicine 13 (1): 24–57.PubMedPubMedCentral
104.
Zurück zum Zitat Vogl, T., A.L. Gharibyan, and L.A. Morozova-Roche. 2012. Pro-inflammatory S100A8 and S100A9 proteins: Self-assembly into multifunctional native and amyloid complexes. International Journal of Molecular Sciences 13 (3): 2893–2917.PubMedPubMedCentral Vogl, T., A.L. Gharibyan, and L.A. Morozova-Roche. 2012. Pro-inflammatory S100A8 and S100A9 proteins: Self-assembly into multifunctional native and amyloid complexes. International Journal of Molecular Sciences 13 (3): 2893–2917.PubMedPubMedCentral
105.
Zurück zum Zitat Austermann, J., S. Zenker, and J. Roth. 2017. S100-alarmins: Potential therapeutic targets for arthritis. Expert Opinion on Therapeutic Targets 21 (7): 738–750. Austermann, J., S. Zenker, and J. Roth. 2017. S100-alarmins: Potential therapeutic targets for arthritis. Expert Opinion on Therapeutic Targets 21 (7): 738–750.
106.
Zurück zum Zitat Wang, Q., W. Chen, and J. Lin. 2019. The role of calprotectin in rheumatoid arthritis. Journal of Translational Medicine 7 (4): 126–131. Wang, Q., W. Chen, and J. Lin. 2019. The role of calprotectin in rheumatoid arthritis. Journal of Translational Medicine 7 (4): 126–131.
107.
Zurück zum Zitat Chen, Y.S., W. Yan, C.L. Geczy, M.A. Brown, and R. Thomas. 2009. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis research & therapy 11 (2): R39. Chen, Y.S., W. Yan, C.L. Geczy, M.A. Brown, and R. Thomas. 2009. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis research & therapy 11 (2): R39.
108.
Zurück zum Zitat Bianchi, R., E. Kastrisianaki, I. Giambanco, and R. Donato. 2011. S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release. The Journal of biological chemistry 286 (9): 7214–7226.PubMedPubMedCentral Bianchi, R., E. Kastrisianaki, I. Giambanco, and R. Donato. 2011. S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release. The Journal of biological chemistry 286 (9): 7214–7226.PubMedPubMedCentral
109.
Zurück zum Zitat Navratilova, A., V. Becvar, J. Baloun, D. Damgaard, C.H. Nielsen, D. Veigl, K. Pavelka, J. Vencovsky, L. Šenolt, and L. Andres Cerezo. 2021. S100A11 (calgizzarin) is released via NETosis in rheumatoid arthritis (RA) and stimulates IL-6 and TNF secretion by neutrophils. Scientific reports 11 (1): 6063.PubMedPubMedCentral Navratilova, A., V. Becvar, J. Baloun, D. Damgaard, C.H. Nielsen, D. Veigl, K. Pavelka, J. Vencovsky, L. Šenolt, and L. Andres Cerezo. 2021. S100A11 (calgizzarin) is released via NETosis in rheumatoid arthritis (RA) and stimulates IL-6 and TNF secretion by neutrophils. Scientific reports 11 (1): 6063.PubMedPubMedCentral
110.
Zurück zum Zitat Xue, J., R. Ray, D. Singer, D. Böhme, D.S. Burz, V. Rai, R. Hoffmann, and A. Shekhtman. 2014. The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGEs. Biochemistry 53 (20): 3327–3335.PubMed Xue, J., R. Ray, D. Singer, D. Böhme, D.S. Burz, V. Rai, R. Hoffmann, and A. Shekhtman. 2014. The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGEs. Biochemistry 53 (20): 3327–3335.PubMed
111.
Zurück zum Zitat Bourajjaj, M., C.D. Stehouwer, V.W. van Hinsbergh, and C.G. Schalkwijk. 2003. Role of methylglyoxal adducts in the development of vascular complications in diabetes mellitus. Biochemical Society Transactions 31 (Pt 6): 1400–1402.PubMed Bourajjaj, M., C.D. Stehouwer, V.W. van Hinsbergh, and C.G. Schalkwijk. 2003. Role of methylglyoxal adducts in the development of vascular complications in diabetes mellitus. Biochemical Society Transactions 31 (Pt 6): 1400–1402.PubMed
112.
Zurück zum Zitat Wetzels, S., T. Vanmierlo, J.L.J.M. Scheijen, J. van Horssen, S. Amor, V. Somers, C.G. Schalkwijk, J.J.A. Hendriks, and K. Wouters. 2019. Methylglyoxal-derived advanced glycation endproducts accumulate in multiple sclerosis lesions. Frontiers in Immunology 10: 855.PubMedPubMedCentral Wetzels, S., T. Vanmierlo, J.L.J.M. Scheijen, J. van Horssen, S. Amor, V. Somers, C.G. Schalkwijk, J.J.A. Hendriks, and K. Wouters. 2019. Methylglyoxal-derived advanced glycation endproducts accumulate in multiple sclerosis lesions. Frontiers in Immunology 10: 855.PubMedPubMedCentral
113.
Zurück zum Zitat Lugo-Huitrón, R., P. Ugalde Muñiz, B. Pineda, J. Pedraza-Chaverrí, C. Ríos, and V. Pérez-de la Cruz. 2013. Quinolinic acid: an endogenous neurotoxin with multiple targets. Oxidative Medicine and Cellular Longevity 2013: 104024. Lugo-Huitrón, R., P. Ugalde Muñiz, B. Pineda, J. Pedraza-Chaverrí, C. Ríos, and V. Pérez-de la Cruz. 2013. Quinolinic acid: an endogenous neurotoxin with multiple targets. Oxidative Medicine and Cellular Longevity 2013: 104024.
114.
Zurück zum Zitat Bansal, Y., R. Singh, I. Parhar, A. Kuhad, and T. Soga. 2019. Quinolinic acid and nuclear factor erythroid 2-related factor 2 in depression: Role in neuroprogression. Frontiers in Pharmacology 10: 452.PubMedPubMedCentral Bansal, Y., R. Singh, I. Parhar, A. Kuhad, and T. Soga. 2019. Quinolinic acid and nuclear factor erythroid 2-related factor 2 in depression: Role in neuroprogression. Frontiers in Pharmacology 10: 452.PubMedPubMedCentral
115.
Zurück zum Zitat Huang, Y.S., J. Ogbechi, F.I. Clanchy, R.O. Williams, and T.W. Stone. 2020. IDO and kynurenine metabolites in peripheral and CNS disorders. Frontiers in Immunology 11: 388.PubMedPubMedCentral Huang, Y.S., J. Ogbechi, F.I. Clanchy, R.O. Williams, and T.W. Stone. 2020. IDO and kynurenine metabolites in peripheral and CNS disorders. Frontiers in Immunology 11: 388.PubMedPubMedCentral
116.
Zurück zum Zitat Salgado-Polo, F., A. Fish, M.T. Matsoukas, T. Heidebrecht, W.J. Keune, and A. Perrakis. 2018. Lysophosphatidic acid produced by autotaxin acts as an allosteric modulator of its catalytic efficiency. Journal of Biological Chemistry 293 (37): 14312–14327. Salgado-Polo, F., A. Fish, M.T. Matsoukas, T. Heidebrecht, W.J. Keune, and A. Perrakis. 2018. Lysophosphatidic acid produced by autotaxin acts as an allosteric modulator of its catalytic efficiency. Journal of Biological Chemistry 293 (37): 14312–14327.
117.
Zurück zum Zitat Miyabe, C., Y. Miyabe, J. Nagai, N.N. Miura, N. Ohno, J. Chun, R. Tsuboi, H. Ueda, M. Miyasaka, N. Miyasaka, and T. Nanki. 2019. Abrogation of lysophosphatidic acid receptor 1 ameliorates murine vasculitis. Arthritis Research & Therapy 21 (1): 191. Miyabe, C., Y. Miyabe, J. Nagai, N.N. Miura, N. Ohno, J. Chun, R. Tsuboi, H. Ueda, M. Miyasaka, N. Miyasaka, and T. Nanki. 2019. Abrogation of lysophosphatidic acid receptor 1 ameliorates murine vasculitis. Arthritis Research & Therapy 21 (1): 191.
118.
Zurück zum Zitat Miyabe, Y., C. Miyabe, Y. Iwai, A. Takayasu, S. Fukuda, W. Yokoyama, J. Nagai, M. Jona, Y. Tokuhara, R. Ohkawa, H.M. Albers, H. Ovaa, J. Aoki, J. Chun, Y. Yatomi, H. Ueda, M. Miyasaka, N. Miyasaka, and T. Nanki T. 2013. Necessity of lysophosphatidic acid receptor 1 for development of arthritis. Arthritis & Rheumatology 65 (8): 2037–2047. Miyabe, Y., C. Miyabe, Y. Iwai, A. Takayasu, S. Fukuda, W. Yokoyama, J. Nagai, M. Jona, Y. Tokuhara, R. Ohkawa, H.M. Albers, H. Ovaa, J. Aoki, J. Chun, Y. Yatomi, H. Ueda, M. Miyasaka, N. Miyasaka, and T. Nanki T. 2013. Necessity of lysophosphatidic acid receptor 1 for development of arthritis. Arthritis & Rheumatology 65 (8): 2037–2047.
119.
Zurück zum Zitat Rai, V., F. Touré, S. Chitayat, R. Pei, F. Song, Q. Li, J. Zhang, R. Rosario, R. Ramasamy, W.J. Chazin, and A.M. Schmidt. 2012. Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling. Journal of Experimental Medicine 209 (13): 2339–2350. Rai, V., F. Touré, S. Chitayat, R. Pei, F. Song, Q. Li, J. Zhang, R. Rosario, R. Ramasamy, W.J. Chazin, and A.M. Schmidt. 2012. Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling. Journal of Experimental Medicine 209 (13): 2339–2350.
120.
Zurück zum Zitat Howard, E.W., R. Benton, J. Ahern-Moore, and J.J. Tomasek. 1996. Cellular contraction of collagen lattices is inhibited by nonenzymatic glycation. Experimental cell research 228 (1): 132–137.PubMed Howard, E.W., R. Benton, J. Ahern-Moore, and J.J. Tomasek. 1996. Cellular contraction of collagen lattices is inhibited by nonenzymatic glycation. Experimental cell research 228 (1): 132–137.PubMed
121.
Zurück zum Zitat Tatsuro, E., K. Kohei, Y. Takumi, F. Mami, G. Katsumasa, and H. Tatsuya. 2021. The Effect of Glycation Stress on Skeletal Muscle. Intechopen. Tatsuro, E., K. Kohei, Y. Takumi, F. Mami, G. Katsumasa, and H. Tatsuya. 2021. The Effect of Glycation Stress on Skeletal Muscle. Intechopen.
122.
Zurück zum Zitat Ahmed, A.K., S. Muniandy, and I. Ismail. 2007. Role of N-(carboxymethyl) lysine in the development of ischemic heart disease in type 2 diabetes mellitus. Journal of clinical biochemistry and nutrition 41 (2): 97–105. Ahmed, A.K., S. Muniandy, and I. Ismail. 2007. Role of N-(carboxymethyl) lysine in the development of ischemic heart disease in type 2 diabetes mellitus. Journal of clinical biochemistry and nutrition 41 (2): 97–105.
123.
Zurück zum Zitat Vytášek, R., L. Sedova, and V. Vilím. 2010. Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis. BMC Musculoskeletal Disorder 11: 83. Vytášek, R., L. Sedova, and V. Vilím. 2010. Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis. BMC Musculoskeletal Disorder 11: 83.
124.
Zurück zum Zitat Hitchon, C.A., and H.S. El-Gabalawy. 2004. Oxidation in rheumatoid arthritis. Arthritis Research & Therapy 6 (6): 265–278. Hitchon, C.A., and H.S. El-Gabalawy. 2004. Oxidation in rheumatoid arthritis. Arthritis Research & Therapy 6 (6): 265–278.
125.
Zurück zum Zitat Chimenti, M.S., P. Triggianese, P. Conigliaro, E. Candi, G. Melino, and R. Perricone. 2015. The interplay between inflammation and metabolism in rheumatoid arthritis. Cell Death & Disease 6 (9): e1887. Chimenti, M.S., P. Triggianese, P. Conigliaro, E. Candi, G. Melino, and R. Perricone. 2015. The interplay between inflammation and metabolism in rheumatoid arthritis. Cell Death & Disease 6 (9): e1887.
126.
Zurück zum Zitat Virella, G., S.R. Thorpe, N.L. Alderson, E.M. Stephan, D. Atchley, F. Wagner, M.F. Lopes-Virella, and DCCT/EDIC Research Group. 2003. Autoimmune response to advanced glycosylation end-products of human LDL. Journal of Lipid Research 44 (3): 487–493.PubMed Virella, G., S.R. Thorpe, N.L. Alderson, E.M. Stephan, D. Atchley, F. Wagner, M.F. Lopes-Virella, and DCCT/EDIC Research Group. 2003. Autoimmune response to advanced glycosylation end-products of human LDL. Journal of Lipid Research 44 (3): 487–493.PubMed
127.
Zurück zum Zitat Srikanth, V., A. Maczurek, T. Phan, M. Steele, B. Westcott, D. Juskiw, and G. Münch. 2011. Advanced glycation endproducts and their receptor RAGE in Alzheimer’s disease. Neurobiology of Aging 32 (5): 763–777.PubMed Srikanth, V., A. Maczurek, T. Phan, M. Steele, B. Westcott, D. Juskiw, and G. Münch. 2011. Advanced glycation endproducts and their receptor RAGE in Alzheimer’s disease. Neurobiology of Aging 32 (5): 763–777.PubMed
128.
Zurück zum Zitat Yamagishi, S.I., N. Nakamura, and T. Matsui. 2017. Glycation and cardiovascular disease in diabetes: A perspective on the concept of metabolic memory. Journal of Diabetes 9 (2): 141–148.PubMed Yamagishi, S.I., N. Nakamura, and T. Matsui. 2017. Glycation and cardiovascular disease in diabetes: A perspective on the concept of metabolic memory. Journal of Diabetes 9 (2): 141–148.PubMed
129.
Zurück zum Zitat Saudek, D.M., and J. Kay. 2005. Advanced glycation endproducts and osteoarthritis. Current Rheumatology Reports 5 (1): 33–40. Saudek, D.M., and J. Kay. 2005. Advanced glycation endproducts and osteoarthritis. Current Rheumatology Reports 5 (1): 33–40.
130.
Zurück zum Zitat Dattilo, B.M., G. Fritz, E. Leclerc, C.W. Kooi, C.W. Heizmann, and W.J. Chazin. 2007. The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry 46 (23): 6957–6970.PubMed Dattilo, B.M., G. Fritz, E. Leclerc, C.W. Kooi, C.W. Heizmann, and W.J. Chazin. 2007. The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry 46 (23): 6957–6970.PubMed
131.
Zurück zum Zitat Bierhaus, A., S. Schiekofer, M. Schwaninger, M. Andrassy, P.M. Humpert, J. Chen, M. Hon, T. Luther, T. Henle, I. Klöting, M. Morcos, M. Hofmann, H. Tritschler, B. Weigle, M. Kasper, M. Smith, G. Perry, A.M. Schmidt, D.M. Stern, H.U. Häring, E. Schleicher, and P.P. Nawroth. 2001. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50 (12): 2792–2808.PubMed Bierhaus, A., S. Schiekofer, M. Schwaninger, M. Andrassy, P.M. Humpert, J. Chen, M. Hon, T. Luther, T. Henle, I. Klöting, M. Morcos, M. Hofmann, H. Tritschler, B. Weigle, M. Kasper, M. Smith, G. Perry, A.M. Schmidt, D.M. Stern, H.U. Häring, E. Schleicher, and P.P. Nawroth. 2001. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50 (12): 2792–2808.PubMed
132.
Zurück zum Zitat Ramasamy, R., S.F. Yan, and A.M. Schmidt. 2009. RAGE: Therapeutic target and biomarker of the inflammatory response–the evidence mounts. Journal of Leukocyte Biology 86 (3): 505–512.PubMed Ramasamy, R., S.F. Yan, and A.M. Schmidt. 2009. RAGE: Therapeutic target and biomarker of the inflammatory response–the evidence mounts. Journal of Leukocyte Biology 86 (3): 505–512.PubMed
133.
Zurück zum Zitat Bongarzone, S., V. Savickas, F. Luzi, and A.D. Gee. 2017. Targeting the receptor for advanced glycation endproducts (RAGE): A medicinal chemistry perspective. Journal of Medicinal Chemistry 60 (17): 7213–7232.PubMedPubMedCentral Bongarzone, S., V. Savickas, F. Luzi, and A.D. Gee. 2017. Targeting the receptor for advanced glycation endproducts (RAGE): A medicinal chemistry perspective. Journal of Medicinal Chemistry 60 (17): 7213–7232.PubMedPubMedCentral
134.
Zurück zum Zitat Wu, C., X. Du, L. Tang, J. Wu, W. Zhao, X. Guo, D. Liu, W. Liu, H. Helmby, G. Chen, and Z. Wang. 2020. Schistosoma japonicum SjE16.7 protein promotes tumor development via the receptor for advanced glycation end products (RAGE). Frontiers in Immunology 11: 1767. Wu, C., X. Du, L. Tang, J. Wu, W. Zhao, X. Guo, D. Liu, W. Liu, H. Helmby, G. Chen, and Z. Wang. 2020. Schistosoma japonicum SjE16.7 protein promotes tumor development via the receptor for advanced glycation end products (RAGE). Frontiers in Immunology 11: 1767.
135.
Zurück zum Zitat Heo, Y.J., H.J. Oh, Y.O. Jung, M.L. Cho, S.Y. Lee, J.G. Yu, M.K. Park, H.R. Kim, S.H. Lee, S.H. Park, and H.Y. Kim. 2011. The expression of the receptor for advanced glycation end-products (RAGE) in RA-FLS is induced by IL-17 via Act-1. Arthritis Research & Therapy 13 (4): R113. Heo, Y.J., H.J. Oh, Y.O. Jung, M.L. Cho, S.Y. Lee, J.G. Yu, M.K. Park, H.R. Kim, S.H. Lee, S.H. Park, and H.Y. Kim. 2011. The expression of the receptor for advanced glycation end-products (RAGE) in RA-FLS is induced by IL-17 via Act-1. Arthritis Research & Therapy 13 (4): R113.
136.
Zurück zum Zitat Bednarska, K., and I. Fecka. 2021. Potential of Vasoprotectives to Inhibit Non-Enzymatic Protein Glycation, and Reactive Carbonyl and Oxygen Species Uptake. International Journal of Molecular Sciences 22 :10026 Bednarska, K., and I. Fecka.  2021. Potential of Vasoprotectives to Inhibit Non-Enzymatic Protein Glycation, and Reactive Carbonyl and Oxygen Species Uptake. International Journal of Molecular Sciences 22 :10026
137.
Zurück zum Zitat Davies, S.S., and L.S. Zhang. 2017. Reactive carbonyl species scavengers-novel therapeutic approaches for chronic diseases. Current pharmacology reports 3 (2): 51–67.PubMedPubMedCentral Davies, S.S., and L.S. Zhang. 2017. Reactive carbonyl species scavengers-novel therapeutic approaches for chronic diseases. Current pharmacology reports 3 (2): 51–67.PubMedPubMedCentral
138.
Zurück zum Zitat Nenna, A., F. Nappi, S.S. Avtaar Singh, F.W. Sutherland, F. Di Domenico, M. Chello, and C. Spadaccio. 2015. Pharmacologic approaches against advanced glycation end products (AGEs) in diabetic cardiovascular disease. Research in cardiovascular medicine 4 (2): e26949. Nenna, A., F. Nappi, S.S. Avtaar Singh, F.W. Sutherland, F. Di Domenico, M. Chello, and C. Spadaccio. 2015. Pharmacologic approaches against advanced glycation end products (AGEs) in diabetic cardiovascular disease. Research in cardiovascular medicine 4 (2): e26949.
139.
Zurück zum Zitat Zieman, S.J., V. Melenovsky, L. Clattenburg, M.C. Corretti, A. Capriotti, G. Gerstenblith, and D.A. Kass. 2007. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. Journal of hypertension 25 (3): 577–583.PubMed Zieman, S.J., V. Melenovsky, L. Clattenburg, M.C. Corretti, A. Capriotti, G. Gerstenblith, and D.A. Kass. 2007. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. Journal of hypertension 25 (3): 577–583.PubMed
140.
Zurück zum Zitat Huebschmann, A.G., J.G. Regensteiner, H. Vlassara, and J.E. Reusch. 2006. Diabetes and advanced glycoxidation end products. Diabetes Care 29 (6): 1420–1432.PubMed Huebschmann, A.G., J.G. Regensteiner, H. Vlassara, and J.E. Reusch. 2006. Diabetes and advanced glycoxidation end products. Diabetes Care 29 (6): 1420–1432.PubMed
141.
Zurück zum Zitat Berrone, E., E. Beltramo, C. Solimine, A.U. Ape, and M. Porta. 2006. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. The Journal of biological chemistry 281 (14): 9307–9313.PubMed Berrone, E., E. Beltramo, C. Solimine, A.U. Ape, and M. Porta. 2006. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. The Journal of biological chemistry 281 (14): 9307–9313.PubMed
142.
Zurück zum Zitat Ramis, R., J. Ortega-Castro, C. Caballero, R. Casasnovas, A. Cerrillo, B. Vilanova, M. Adrover, and J. Frau. 2019. How does pyridoxamine inhibit the formation of advanced glycation end products? The role of its primary antioxidant activity. Antioxidants (Basel Switzerland) 8 (9): 344.PubMedCentral Ramis, R., J. Ortega-Castro, C. Caballero, R. Casasnovas, A. Cerrillo, B. Vilanova, M. Adrover, and J. Frau. 2019. How does pyridoxamine inhibit the formation of advanced glycation end products? The role of its primary antioxidant activity. Antioxidants (Basel Switzerland) 8 (9): 344.PubMedCentral
143.
Zurück zum Zitat Yoshii, K., K. Hosomi, and K, Sawane, and J. Kunisawa. 2019. Metabolism of dietary and microbial vitamin b family in the regulation of host immunity. Frontiers in nutrition 6: 48.PubMedPubMedCentral Yoshii, K., K. Hosomi, and K, Sawane, and J. Kunisawa. 2019. Metabolism of dietary and microbial vitamin b family in the regulation of host immunity. Frontiers in nutrition 6: 48.PubMedPubMedCentral
144.
Zurück zum Zitat Syngle, A., K. Vohra, N. Garg, L. Kaur, and P. Chand. 2012. Advanced glycation end-products inhibition improves endothelial dysfunction in rheumatoid arthritis. International journal of rheumatic diseases 15 (1): 45–55.PubMed Syngle, A., K. Vohra, N. Garg, L. Kaur, and P. Chand. 2012. Advanced glycation end-products inhibition improves endothelial dysfunction in rheumatoid arthritis. International journal of rheumatic diseases 15 (1): 45–55.PubMed
145.
Zurück zum Zitat Price, D.L., P.M. Rhett, S.R. Thorpe, and J.W. Baynes. 2001. Chelating activity of advanced glycation end-product inhibitors. The Journal of biological chemistry 276 (52): 48967–48972.PubMed Price, D.L., P.M. Rhett, S.R. Thorpe, and J.W. Baynes. 2001. Chelating activity of advanced glycation end-product inhibitors. The Journal of biological chemistry 276 (52): 48967–48972.PubMed
146.
Zurück zum Zitat Pullerits, R., M. Bokarewa, L. Dahlberg, and A. Tarkowski. 2005. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis research & therapy 7 (4): R817–R824. Pullerits, R., M. Bokarewa, L. Dahlberg, and A. Tarkowski. 2005. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis research & therapy 7 (4): R817–R824.
147.
Zurück zum Zitat Chen, J.H., X. Lin, C. Bu, and X. Zhang. 2018. Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies. Nutrition & metabolism 15: 72. Chen, J.H., X. Lin, C. Bu, and X. Zhang. 2018. Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies. Nutrition & metabolism 15: 72.
148.
Zurück zum Zitat Van Putte, L., S. De Schrijver, and P. Moortgat. 2016. The effects of advanced glycation end products (AGEs) on dermal wound healing and scar formation: A systematic review. Scars burns & healing 2: 2059513116676828. Van Putte, L., S. De Schrijver, and P. Moortgat. 2016. The effects of advanced glycation end products (AGEs) on dermal wound healing and scar formation: A systematic review. Scars burns & healing 2: 2059513116676828.
149.
Zurück zum Zitat Mirmiranpour, H., S.Z. Bathaie, S. Khaghani, M. Nakhjavani, and A. Kebriaeezadeh. 2021. L-lysine supplementation improved glycemic control, decreased protein glycation, and insulin resistance in type 2 diabetic patients. International Journal of Diabetes in Developing Countries. Mirmiranpour, H., S.Z. Bathaie, S. Khaghani, M. Nakhjavani, and A. Kebriaeezadeh. 2021. L-lysine supplementation improved glycemic control, decreased protein glycation, and insulin resistance in type 2 diabetic patients. International Journal of Diabetes in Developing Countries.
150.
Zurück zum Zitat Mouterde, G., N. Rincheval, C. Lukas, C. Daien, A. Saraux, P. Dieudé, J. Morel, and B. Combe. 2019. Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort. Arthritis Research & Therapy 21 (1): 140. Mouterde, G., N. Rincheval, C. Lukas, C. Daien, A. Saraux, P. Dieudé, J. Morel, and B. Combe. 2019. Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort. Arthritis Research & Therapy 21 (1): 140.
151.
Zurück zum Zitat Jounai, N., K. Kobiyama, F. Takeshita, and K.J. Ishii. 2013. Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccination. Frontiers in Cellular and Infection Microbiology 2: 168.PubMedPubMedCentral Jounai, N., K. Kobiyama, F. Takeshita, and K.J. Ishii. 2013. Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccination. Frontiers in Cellular and Infection Microbiology 2: 168.PubMedPubMedCentral
152.
Zurück zum Zitat de Vos, L.C., J.D. Lefrandt, R.P. Dullaart, C.J. Zeebregts, and A.J. Smit. 2016. Advanced glycation end products: An emerging biomarker for adverse outcome in patients with peripheral artery disease. Atherosclerosis 254: 291–299.PubMed de Vos, L.C., J.D. Lefrandt, R.P. Dullaart, C.J. Zeebregts, and A.J. Smit. 2016. Advanced glycation end products: An emerging biomarker for adverse outcome in patients with peripheral artery disease. Atherosclerosis 254: 291–299.PubMed
153.
Zurück zum Zitat Gopal, P., N.L. Reynaert, J.L. Scheijen, L. Engelen, C.G. Schalkwijk, F.M. Franssen, E.F. Wouters, and E.P. Rutten. 2014. Plasma advanced glycation end-products and skin autofluorescence are increased in COPD. The European respiratory journal 43 (2): 430–438.PubMed Gopal, P., N.L. Reynaert, J.L. Scheijen, L. Engelen, C.G. Schalkwijk, F.M. Franssen, E.F. Wouters, and E.P. Rutten. 2014. Plasma advanced glycation end-products and skin autofluorescence are increased in COPD. The European respiratory journal 43 (2): 430–438.PubMed
154.
Zurück zum Zitat Băbţan, A.M., A. Ilea, B.A. Boşca, M. Crişan, N.B. Petrescu, M. Collino, R.M. Sainz, J.Q. Gerlach, and R.S. Câmpian. 2019. Advanced glycation end products as biomarkers in systemic diseases: Premises and perspectives of salivary advanced glycation end products. Biomarkers in medicine 13 (6): 479–495.PubMed Băbţan, A.M., A. Ilea, B.A. Boşca, M. Crişan, N.B. Petrescu, M. Collino, R.M. Sainz, J.Q. Gerlach, and R.S. Câmpian. 2019. Advanced glycation end products as biomarkers in systemic diseases: Premises and perspectives of salivary advanced glycation end products. Biomarkers in medicine 13 (6): 479–495.PubMed
155.
Zurück zum Zitat Hanssen, N.M., K. Wouters, M.S. Huijberts, M.J. Gijbels, J.C. Sluimer, J.L. Scheijen, S. Heeneman, E.A. Biessen, M.J. Daemen, M. Brownlee, D.P. de Kleijn, C.D. Stehouwer, G. Pasterkamp, and C.G. Schalkwijk. 2014. Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. European heart journal 35 (17): 1137–1146.PubMed Hanssen, N.M., K. Wouters, M.S. Huijberts, M.J. Gijbels, J.C. Sluimer, J.L. Scheijen, S. Heeneman, E.A. Biessen, M.J. Daemen, M. Brownlee, D.P. de Kleijn, C.D. Stehouwer, G. Pasterkamp, and C.G. Schalkwijk. 2014. Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. European heart journal 35 (17): 1137–1146.PubMed
156.
Zurück zum Zitat Martinez Fernandez, A., L. Regazzoni, M. Bioschi, E. Gianazza, P. Agostoni, G. Aldini, and C. Banfi. 2019. Pro-oxidant and pro-inflammatory effects of glycated albumin on cardiomyocytes. Free radical biology & medicine 144: 245–255. Martinez Fernandez, A., L. Regazzoni, M. Bioschi, E. Gianazza, P. Agostoni, G. Aldini, and C. Banfi. 2019. Pro-oxidant and pro-inflammatory effects of glycated albumin on cardiomyocytes. Free radical biology & medicine 144: 245–255.
157.
Zurück zum Zitat Park, J.S., J. Song, Y.B. Park, S.K. Lee, and S.W. Lee. 2017. Glycated albumin increases with disease activity in rheumatoid factor positive rheumatoid arthritis patients with normal fasting glucose and HbA1c. Joint, Bone, Spine 84 (1): 115–118. Park, J.S., J. Song, Y.B. Park, S.K. Lee, and S.W. Lee. 2017. Glycated albumin increases with disease activity in rheumatoid factor positive rheumatoid arthritis patients with normal fasting glucose and HbA1c. Joint, Bone, Spine 84 (1): 115–118.
158.
Zurück zum Zitat Ben-Hadj-Mohamed, M., S. Khelil, M. Ben Dbibis, L. Khlifi, H. Chahed, S. Ferchichi, E. Bouajina, and A. Miled. 2017. Hepatic proteins and inflammatory markers in rheumatoid arthritis patients. Iranian Journal of Public Health 46 (8): 1071–1078.PubMedPubMedCentral Ben-Hadj-Mohamed, M., S. Khelil, M. Ben Dbibis, L. Khlifi, H. Chahed, S. Ferchichi, E. Bouajina, and A. Miled. 2017. Hepatic proteins and inflammatory markers in rheumatoid arthritis patients. Iranian Journal of Public Health 46 (8): 1071–1078.PubMedPubMedCentral
159.
Zurück zum Zitat Bergum, B., C. Koro, N. Delaleu, M. Solheim, A. Hellvard, V. Binder, R. Jonsson, V. Valim, D.S. Hammenfors, M.V. Jonsson, and P. Mydel. 2016. Antibodies against carbamylated proteins are present in primary Sjögren’s syndrome and are associated with disease severity. Annals of the Rheumatic Diseases 75 (8): 1494–1500.PubMed Bergum, B., C. Koro, N. Delaleu, M. Solheim, A. Hellvard, V. Binder, R. Jonsson, V. Valim, D.S. Hammenfors, M.V. Jonsson, and P. Mydel. 2016. Antibodies against carbamylated proteins are present in primary Sjögren’s syndrome and are associated with disease severity. Annals of the Rheumatic Diseases 75 (8): 1494–1500.PubMed
160.
Zurück zum Zitat Dunn, E.J., H. Philippou, R.A. Ariëns, and P.J. Grant. 2006. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 49 (5): 1071–1080.PubMed Dunn, E.J., H. Philippou, R.A. Ariëns, and P.J. Grant. 2006. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 49 (5): 1071–1080.PubMed
161.
Zurück zum Zitat Lapolla, A., D. Fedele, M. Garbeglio, L. Martano, R. Tonani, R. Seraglia, D. Favretto, M.A. Fedrigo, and P. Traldi. 2000. Matrix-assisted laser desorption/ionization mass spectrometry, enzymatic digestion and molecular modeling in the study of nonenzymatic glycation of IgG. Journal of the American Society for Mass Spectrometry 11 (2): 153–159.PubMed Lapolla, A., D. Fedele, M. Garbeglio, L. Martano, R. Tonani, R. Seraglia, D. Favretto, M.A. Fedrigo, and P. Traldi. 2000. Matrix-assisted laser desorption/ionization mass spectrometry, enzymatic digestion and molecular modeling in the study of nonenzymatic glycation of IgG. Journal of the American Society for Mass Spectrometry 11 (2): 153–159.PubMed
162.
Zurück zum Zitat Spiller, S., Y. Li, M. Blüher, L. Welch, and R. Hoffmann. 2018. Diagnostic accuracy of protein glycation sites in long-term controlled patients with type 2 diabetes mellitus and their prognostic potential for early diagnosis. Pharmaceuticals (Basel) 11 (2): 38. Spiller, S., Y. Li, M. Blüher, L. Welch, and R. Hoffmann. 2018. Diagnostic accuracy of protein glycation sites in long-term controlled patients with type 2 diabetes mellitus and their prognostic potential for early diagnosis. Pharmaceuticals (Basel) 11 (2): 38.
163.
Zurück zum Zitat Nobécourt, E., F. Tabet, G. Lambert, R. Puranik, S. Bao, L. Yan, M.J. Davies, B.E. Brown, A.J. Jenkins, G.J. Dusting, D.J. Bonnet, L.K. Curtiss, P.J. Barter, and K.A. Rye. 2010. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arteriosclerosis thrombosis and vascular biology 30 (4): 766–772. Nobécourt, E., F. Tabet, G. Lambert, R. Puranik, S. Bao, L. Yan, M.J. Davies, B.E. Brown, A.J. Jenkins, G.J. Dusting, D.J. Bonnet, L.K. Curtiss, P.J. Barter, and K.A. Rye. 2010. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arteriosclerosis thrombosis and vascular biology 30 (4): 766–772.
164.
Zurück zum Zitat Sabitha, D., E. Dawson, S. Tiwari, P. Swetha, S.M. Naushad, K.S. Baba, S. Sai, I.K. Mohan, and G.U. Rani. 2020. Study of glycation of transferrin and its effect on biomarkers of iron status in uncontrolled diabetes mellitus patients. Journal of Clinical & Diagnostic Research 14 (8): BC06-BC09. Sabitha, D., E. Dawson, S. Tiwari, P. Swetha, S.M. Naushad, K.S. Baba, S. Sai, I.K. Mohan, and G.U. Rani. 2020. Study of glycation of transferrin and its effect on biomarkers of iron status in uncontrolled diabetes mellitus patients. Journal of Clinical & Diagnostic Research 14 (8): BC06-BC09.
165.
Zurück zum Zitat Kumar, S., and M. Dikshit. 2019. Metabolic insight of neutrophils in health and disease. Frontiers in immunology 10: 2099.PubMedPubMedCentral Kumar, S., and M. Dikshit. 2019. Metabolic insight of neutrophils in health and disease. Frontiers in immunology 10: 2099.PubMedPubMedCentral
166.
Zurück zum Zitat Najafizadeh, S.R., K. Amiri, M. Moghaddassi, S. Khanmohammadi, H. Mirmiranpour, and M. Nakhjavani. 2021. Advanced glycation end products advanced oxidation protein products and ferric reducing ability of plasma in patients with rheumatoid arthritis: A focus on activity scores. Clinical Rheumatology 40: 4019–4026. https://doi.org/10.1007/s10067-021-05771-y.CrossRefPubMed Najafizadeh, S.R., K. Amiri, M. Moghaddassi, S. Khanmohammadi, H. Mirmiranpour, and M. Nakhjavani. 2021. Advanced glycation end products advanced oxidation protein products and ferric reducing ability of plasma in patients with rheumatoid arthritis: A focus on activity scores. Clinical Rheumatology 40: 4019–4026. https://​doi.​org/​10.​1007/​s10067-021-05771-y.CrossRefPubMed
167.
Zurück zum Zitat Schroter, D., and A. Hohn. 2018. Role of advanced glycation end products in carcinogenesis and their therapeutic implications. Current Pharmaceutical Design 24 (44): 5245–5251.PubMed Schroter, D., and A. Hohn. 2018. Role of advanced glycation end products in carcinogenesis and their therapeutic implications. Current Pharmaceutical Design 24 (44): 5245–5251.PubMed
168.
Zurück zum Zitat Li, Y., M.S. Khan, F. Akhter, F.M. Husain, S. Ahmad, and L. Chen. 2019. The non-enzymatic glycation of LDL proteins results in biochemical alterations - a correlation study of Apo B100-AGE with obesity and rheumatoid arthritis. International Journal of Biological Macromolecules 122: 195–200.PubMed Li, Y., M.S. Khan, F. Akhter, F.M. Husain, S. Ahmad, and L. Chen. 2019. The non-enzymatic glycation of LDL proteins results in biochemical alterations - a correlation study of Apo B100-AGE with obesity and rheumatoid arthritis. International Journal of Biological Macromolecules 122: 195–200.PubMed
Metadaten
Titel
AGE/Non-AGE Glycation: An Important Event in Rheumatoid Arthritis Pathophysiology
verfasst von
Monu
Prachi Agnihotri
Sagarika Biswas
Publikationsdatum
17.11.2021
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 2/2022
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-021-01589-7

Weitere Artikel der Ausgabe 2/2022

Inflammation 2/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.